4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/BML-258 HCl/1/406472
商品详细MedKoo/BML-258 HCl/1/406472
MedKoo/BML-258 HCl/1/406472
MedKoo/BML-258 HCl/1/406472
商品编号: 406472
品牌: MedKoo
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

BML-258 HCl

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406472

CAS#:1072443-89-0

Description:BML-258 HCl was removedand discontinued.

Price and Availability

SizePriceShipping out timeQuantity
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

BML258 HCl was discontinued.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406472Name: BML-258 HClCAS#: 1072443-89-0Chemical Formula: C17H28ClNO2Exact Mass: Molecular Weight: 313.86272Elemental Analysis: C, 65.05; H, 8.99; Cl, 11.30; N, 4.46; O, 10.20

Synonym:BML258; BML 258; BML-258; SK1I.

IUPAC/Chemical Name:(2R,3S,E)-2-(methylamino)-5-(4-pentylphenyl)pent-4-ene-1,3-diol hydrochloride

InChi Key:SGCJOKUPGVFNKS-UUCPMUBFSA-N

InChi Code:InChI=1S/C17H27NO2.ClH/c1-3-4-5-6-14-7-9-15(10-8-14)11-12-17(20)16(13-19)18-2;/h7-12,16-20H,3-6,13H2,1-2H3;1H/b12-11+;/t16-,17+;/m1./s1

SMILES Code:OC[C@@H](NC)[C@@H](O)/C=C/C1=CC=C(CCCCC)C=C1.[H]Cl

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Price MM, Oskeritzian CA, Falanga YT, HarikumarKB, Allegood JC, Alvarez SE, Conrad D, Ryan JJ, Milstien S, Spiegel S. Aspecific sphingosine kinase 1 inhibitor attenuates airwayhyperresponsiveness and inflammation in a mast cell-dependent murinemodel of allergic asthma. J Allergy Clin Immunol. 2013Feb;131(2):501-11.e1. doi: 10.1016/j.jaci.2012.07.014. Epub 2012 Aug 30.PubMed PMID: 22939756; PubMed Central PMCID: PMC3563730.

2: Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, YamadaA, Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K.Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breastcancer progression by stimulating angiogenesis and lymphangiogenesis.Cancer Res. 2012 Feb 1;72(3):726-35. doi: 10.1158/0008-5472.CAN-11-2167.PubMed PMID: 22298596; PubMed Central PMCID: PMC3289261.

3: Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactivesphingolipids in resveratrol-induced apoptosis in HL60: acute myeloidleukemia cells. J Cancer Res Clin Oncol. 2011 Feb;137(2):279-86. doi:10.1007/s00432-010-0884-x. Epub 2010 Apr 18. PubMed PMID: 20401667.

4: Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK,Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S. Targetingsphingosine kinase 1 inhibits Akt signaling, induces apoptosis, andsuppresses growth of human glioblastoma cells and xenografts. CancerRes. 2009 Sep 1;69(17):6915-23. doi: 10.1158/0008-5472.CAN-09-0664.PubMed PMID: 19723667; PubMed Central PMCID: PMC2752891.

5: Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T,Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. A selectivesphingosine kinase 1 inhibitor integrates multiple molecular therapeutictargets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91. doi:10.1182/blood-2008-02-138958. Epub 2008 May 29. PubMed PMID: 18511810;PubMed Central PMCID: PMC2515133.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。